Impact of Chronic Viral Hepatitis on Health-Related Quality of Life in HIV

Results from a Nationally Representative Sample

Published in: American Journal of Gastroenterology, v. 100, no. 9, Sep. 2005, p. 1984-1994

Posted on on January 01, 2005

by Fasiha Kanwal, Ian M. Gralnek, Ron D. Hays, Gareth S. Dulai, Brennan M. R. Spiegel, Samuel A. Bozzette, Steven M. Asch

Read More

Access further information on this document at American Journal of Gastroenterology

This article was published outside of RAND. The full text of the article can be found at the link above.

BACKGROUND: Little is known about the health burden of chronic viral hepatitis in HIV-infected patients. The authors compared health-related quality of life (HRQOL) of patients with HIV and hepatitis C virus (HCV) or HIV and hepatitis B virus (HBV) coinfection to those with HIV monoinfection. METHODS: Using a nationally representative sample of 1,874 adults with HIV who completed a baseline and two follow-up interviews, the authors identified those with HIV monoinfection (n = 1,493), HIVHCV coinfection (n = 279), and HIVHBV coinfection (n = 122). The authors measured baseline and change over time scores for physical and mental health (PHS, MHS), overall quality of life (QOL), overall health, and disability days. To identify the independent effect of coinfection, the authors adjusted for demographic and clinical predictors of HRQOL using multivariable regression. RESULTS: Despite significant differences in socio-demographic characteristics between groups, there were no differences in the baseline scores for PHS, MHS, overall QOL, overall health, or disability days between groups. The HRQOL did not decline significantly over time for the HIV patients with or without HCV or HBV coinfection. All groups reported similar longitudinal changes in the HRQOL scores for all measures. CONCLUSIONS: The authors found no significant differences in disease burden as assessed by a generic HRQOL instrument between patients with HIV monoinfection and HIVHCV or HIVHBV coinfection. These data are relevant in counseling coinfected patients regarding the impact of coinfection on HRQOL, and are important in designing clinical trials and conducting cost-effectiveness analyses including this vulnerable cohort.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.